In vivo study of xibornol on phagocyte functions.
Polymorphonuclear leukocytes (PML) represent the first step of defense against bacteria and fungi. Since many antimicrobial drugs have been reported to inhibit phagocyte function, we tested the interference of xibornol, a new antimicrobial agent, on phagocyte functions, in order to evaluate its possible use in chronic respiratory diseases. In the patients treated with xibornol (500 mg every 8 h for 7 days) we did not find any modification in phagocytosis frequency (PMF), phagocytosis index (PHI), nitroblue tetrazolium (NBT), reduction frequency (NRF), microbicidal activity and neutrophil mobility of PML, before, during and after the end of therapy.
D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001892:Camphanes / Q000494:pharmacology*; D006801:Humans; D008875:Middle Aged; D010586:Phagocytes / Q000187:drug effects*; D010587:Phagocytosis / Q000187:drug effects
D000900:Anti-Bacterial Agents; D001892:Camphanes; C003773:xibornol